Multicenter phase II study of trabectedin in patients with metastatic castration-resistant prostate cancer

M. D. Michaelson, J. Bellmunt, G. R. Hudes, S. Goel, R. J. Lee, P. W. Kantoff, C. A. Stein, P. Lardelli, I. Pardos, C. Kahatt, A. Nieto, M. Cullell-Young, N. L. Lewis, M. R. Smith

Research output: Contribution to journalArticlepeer-review

20 Scopus citations


Background: This multicenter phase II trial evaluated the efficacy and safety of trabectedin in metastatic castration-resistant prostate cancer (CRPC). Patients and methods: Two schedules were evaluated in three cohorts: weekly as 3-h i.v. infusion at 0.58 mg/m 2 for 3 out of 4 weeks (Cohort A, n = 33), and every 3 weeks (q3wk) as 24-h infusion at 1.5 mg/m 2 (Cohort B1, n = 5) and 1.2 mg/m 2 (Cohort B2, n = 20). The primary end point was prostate-specific antigen (PSA) response; secondary end points included safety, tolerability and time to progression (TTP). Results: Trabectedin resulted in PSA declines ≥50% in 12.5% (Cohort A) and 10.5% (Cohort B2) of patients. Among men pretreated with taxane-based chemotherapy, PSA response was 13.6% (Cohort A) and 15.4% (Cohort B2). PSA responses lasted 4.1-8.6 months, and median TTP was 1.5 months (Cohort A) and 1.9 months (Cohort B2). The dose of 1.5 mg/m. 2 (approved for soft tissue sarcoma) given as 24-h infusion q3wk was not tolerable in these patients. At 1.2 mg/m. 2 q3wk and 0.58 mg/m. 2 weekly, the most common adverse events were nausea, fatigue and transient neutropenia and transaminase increase. Conclusions: Two different trabectedin schedules showed modest activity in metastatic CRPC. Further studies may require identification of predictive factors of response in prostate cancer.

Original languageEnglish (US)
Pages (from-to)1234-1240
Number of pages7
JournalAnnals of Oncology
Issue number5
StatePublished - May 2012


  • Chemotherapy
  • Docetaxel
  • Prostate cancer
  • Second-line
  • Trabectedin

ASJC Scopus subject areas

  • Hematology
  • Oncology


Dive into the research topics of 'Multicenter phase II study of trabectedin in patients with metastatic castration-resistant prostate cancer'. Together they form a unique fingerprint.

Cite this